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a consecutive 6-month period of stability and were at increased
risk of thromboembolic events and bleeding. Age, morbidity at
baseline and variability of INR control in the ﬁrst three-months
predicted instability using warfarin.
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OBJECTIVES: Atrial ﬁbrillation (AF) remains a major health
problem, affecting 2.2 million adults in the US with an estimated
cost burden of $3 billion annually. Treatment approaches vary
signiﬁcantly and can include both interventional and pharmaco-
logic options. The purpose of this research was to characterize
the clinical and economic impact associated with AF.
METHODS: Patients with continuous health beneﬁt eligibility
and a “new” diagnosis of AF (ICD-9-CM 427.3¥) were identi-
ﬁed from a large, geographically diverse administrative claims
database in the US (N = 43 million) between 1 January 2000 and
31 December 2001 with a variable follow-up period of ≥6
months. Warfarin-treated (WT) (N = 6,846) and untreated (UT)
(N = 40,849) cohorts were evaluated based on initial therapy
associated with the AF diagnosis. Study outcomes included
patient demography, treatment patterns and direct medical costs.
RESULTS: The AF cohorts were comprised of 58.5% males with
a mean age of 57.9 ± 15.8yrs; mean duration of follow-up was
~20 months. WT was initially received by 14% of this AF cohort
with only 37% receiving warfarin sometime during follow-up.
The WT cohort spent approximately 34% of their study follow-
up exposed to warfarin (average number of days on therapy =
206.5; average study duration = 608.7 days). Annualized AF-
related costs were $10,560 ± 290 (WT) versus $10,131 ± 143
(UT). CONCLUSIONS: Signiﬁcant proportions of AF patients
do not receive pharmacotherapy. Furthermore, pharmacotherapy
appeared to be sub-optimal among those who received it. Better
management of AF pharmacotherapy or uses of newer therapies
that provide appropriate anticoagulation are necessary to reduce
the burden associated with this costly disease.
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OBJECTIVE: Atrial Tachyarrhythmias (ATs) currently repre-
sents a major economic burden for society. Italian data on epi-
demiology and hospital costs of (ATs) are lacking. METHODS:
Prospective systematic evaluation of all consecutively Emergency
Room (ER) admitted patients with a diagnosis of AT in the
Alessandria, Novara, Novi Ligure and Tortona Hospitals from
November 2004 to January 2005. A group of clinicians and
economists developed an ad-hoc questionnaire in order to collect
data on hospital resources consumption. RESULTS: A total of
201 patients were enrolled in the study (mean age: 66.2 „b 15.4),
of which 48.8% was male. Most of the patients (80.4%) were
admitted the ER in the ﬁrst 48 hours after the AT event. Out of
the 201 patients (44.3%) declared that was their ﬁrst AT episode.
At the moment of the event 46.7% of the patients were not
assuming any pharmacological therapy, 21.9% were assuming
anti-aggregate, 7.5% anticoagulant, 39.8% anti-arrhythmic
drugs and 5% were already implanted with a Pacemaker. A total
of 818 diagnostic test and therapeutic procedures were per-
formed, which means, on average, 4.1 per patient. The most 
performed were ECG followed by blood test, pharmacological
cardioversion, chest X-ray, in-hospital ECG monitoring, 24-hour
holter monitoring, and external cardioversion. Out of the total
patients, 148 were discharged from the ER, 31 patients were hos-
pitalized in the “department of short-term observation” (average
length of staying (LOS): 1.3 days), 8 patients were hospitalized
in the cardiological department (average LOS: 7 days), 12 were
hospitalized in other departments (average LOS: 4 days) and
only 2 patients had different destination. CONCLUSIONS: This
study shows that ATs, even if they are not life-threatening dis-
eases and most patients are discharged directly from ER, absorb
a relevant amount of hospital resources. Future economic eval-
uation of this data will highlight also the impact of ATs on the
hospital and NHS expenses.
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OBJECTIVES: To establish the current level of resource utilisa-
tion required to monitor International Normalised Ratio (INR)
levels in patients treated with warfarin in the UK National
Health Service. METHODS: Monitoring services in areas asso-
ciated with six secondary care Trusts were studied. Accurate
descriptions of services were obtained through one-to-one semi-
structured interviews with NHS staff involved in the delivery of
anticoagulant monitoring. Due to the complexity of the differ-
ent systems, where possible, resource use was divided into the 3
main steps: taking blood (including transport of patients and/or
bloods), INR analysis, and the communication of results and
warfarin dose changes. Costs associated with running the service
were identiﬁed and sourced from local settings or NHS reference
costs as appropriate (2004 prices). RESULTS: The six monitor-
ing services were responsible for an average of 3459 (Range
1422–4500) warfarin patients, with a mean frequency of INR
monitoring of 14.2 times per year (SD 3.4). The average cost of
a monitoring visit was £14.58 (SD 4.25), of which £6.88 as asso-
ciated with taking bloods, £4.08 with analysis and £3.62 with
communication of results and dose changes. The mean annual
cost per patient of INR monitoring was £206.41 (SD 63.51).
Three of the services had separate hospital and primary/shared
care models of INR monitoring. In these services the cost per
INR test tended to be lower in the hospital based model (Mean
£13.39) than in models that included primary care (Mean
£23.06). CONCLUSIONS: The cost of INR monitoring varies
according to setting and system. Where monitoring involves
primary care, it tends to be more costly than systems in which
hospital anticoagulation clinics control monitoring and warfarin
treatment. This may be due to economies of scale and the ability
of specialist clinics to deal with the monitoring process more 
efﬁciently.
